Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 3Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Parathyroid Diseases 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Mixed Tumor, Mesodermal 1Melanoma 1Margins of Excision 1Lymphoma 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Adenoma 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 22Blood Specimen Collection 18Nivolumab 17Carboplatin 15Standard of Care 14Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8130-nm albumin-bound paclitaxel 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Indocyanine Green × 90 days × Clear all
NCT07149207 2026-05-12

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Medical University of South Carolina

Phase 2 Recruiting
30 enrolled
Head & Neck

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT04084067 2026-04-30

Indocyanine Green (ICG) Guided Tumor Resection

St. Jude Children's Research Hospital

Phase 1 Recruiting
230 enrolled
CNSGastrointestinalGenitourinaryLymphoidSarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lymphoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04752137 2026-04-24

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡